@article{a9bb7ddead154dcd8196e19a2ced7398,
title = "A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6",
abstract = "To assess the efficacy and tolerability of bicalutamide 150 mg ('Casodex'(1)) as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with early (T1b-T4, any N, M0) prostate cancer.",
keywords = "Aged, Aged, 80 and over, Anilides, Antineoplastic Agents, Chemotherapy, Adjuvant, Combined Modality Therapy, Double-Blind Method, Humans, Male, Middle Aged, Neoplasm Staging, Nitriles, Prostatic Neoplasms, Sexual Behavior, Survival Analysis, Time Factors, Tosyl Compounds",
author = "P Iversen and Tammela, {T L J} and S Vaage and O Lukkarinen and P Lodding and T Bull-Njaa and J Viitanen and P Hoisaeter and P Lundmo and F Rasmussen and J-E Johansson and B-E Persson and K Carroll and {Scandinavian Prostatic Cancer Group (SPCG)}",
year = "2002",
language = "English",
volume = "42",
pages = "204--11",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier BV",
number = "3",
}